---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261753"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:55:43.521955+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyell CEO Lynn Seely appointed interim CFO; Veronica Sanchez Bulis named principal accounting officer

## Summary
- Board appointed CEO Lynn Seely as interim principal financial officer on Oct 31, 2025; also remains CEO and director.
- Veronica Sanchez Bulis, VP Corporate Controller since Aug 2021, appointed principal accounting officer.
- Bulis previously held senior finance roles at Sangamo Therapeutics and Core-Mark International; began career at EY and Deloitte.
- No departure or replacement of a named executive officer was disclosed; changes effective immediately.

## SEC filing metadata
- accession: 0001193125-25-261753
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312525261753/0001193125-25-261753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312525261753/d73457d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261753
- JSON: https://secwatch.observer/filing/0001193125-25-261753.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.